Ditemukan 2 dokumen yang sesuai dengan query :: Simpan CSV
Aulia Rizka; Pembimbing: Helda; Penguji: Tri Yunis Miko Wahyono, Trisari Anggondowati, Findy Prasetyawaty, Ridzqie Dibyantari
Abstrak:
Read More
Latar Belakang. Kemoterapi merupakan salah satu modalitas terapi kanker pada pasien usia lanjut yang dapat menyebabkan risiko berat, terutama pada pasien usia lanjut dengan sindrom frailty. Hingga saat ini belum ada model prediksi kemotoksisitas dengan variabel frailty. Penelitian ini bertujuan mengembangkan model prediksi kemotoksisitas berat pada usia lanjut yang melibatkan penilaian status frailty. Metode. Penelitian kohort retrospektif menggunakan data sekunder terhadap pasien usia lanjut yang menjalani kemoterapi di RSCM tahun 2019-2021. Dilakukan pemeriksaan determinan (jenis kelamin, usia, jenis kanker, jumlah regimen kemoterapi, status nutrisi, status frailty, polifarmasi, fungsi kognitif, status fungsional dan depresi) sebelum kemoterapi. Pasien diikuti hingga 21 hari pasca kemoterapi siklus pertama untuk dinilai apakah mengalami luaran kemotoksisitas berat berdasarkan kriteria CTCAE grade 3-5. Dilakukan analisis untuk pengembangan model prediksi dengan regresi Cox dan perhitungan performa prognostiknya menggunakan perangkat SPSS. Hasil. Dari 193 subyek yang menjalani kemoterapi, sebagian besar laki-laki dengan median usia 65,6 (RIK 60-82). Toksisitas berat terjadi pada 36% subyek. Model prediksi yang dikembangkan terdiri dari 4 determinan yaitu polifarmasi, penggunaan regimen kemoterapi lebih dari satu obat, status frailty dan jenis kanker saluran cerna. Model ini memiliki AUC 0,79 (IK95% 0,70-0,88) dengan p=0,01. Kesimpulan. Model prediksi dengan variabel polifarmasi, regimen kemoterapi lebih dari satu, status frailty dan jenis kanker saluran cerna dapat memprediksi kejadian toksisitas berat kemoterapi pada usia lanjut dengan performa baik
Background. Chemotherapy is a therapeutic modality for elderly with cancer which can pose elderly, especially frail patients, to fatal side effect. To date, there is no prediction model incorporating frailty in clincal practice. This study aims to develop prediction model which includes frailty state evaluation in predicting severe chemotoxicity in elderly. Methods. A retrospective cohort study using secondary data of elderly underwent chemotherapy during 2019-2021 was conducted in Cipto Mangunkusumo Hospital. Data of determinants ( sex, age, polypharmacy, frailty status, nutritional status, depression, cognitive status, cancer type, polychemotherapy, and functional status) and the incidence severe chemotherapy side effect according to grade 3-5 CTCAE were collected. Data was analyzed to develop prediction model with Cox regression using SPSS Results. Of 193 subjects, most of them are male, with median age of 65.6 (IQR 60-82) years old. Severe chemotoxicity was found in 36% of the subjects. Prediction model consists of polypharmacy, number of chemotherapy drugs, cancer type and frailty status was developed. The model has AUC of 0.79 (95% CI 0.70-0.88), p value 0,01 Conclusion. A prognostic Model consists of polypharmacy, number of chemotherapy drugs, cancer type and frailty status can predict incidence of severe chemotoxicity in elderly with AUC 0.79 (95%CI 0.70-0.88)
Background. Chemotherapy is a therapeutic modality for elderly with cancer which can pose elderly, especially frail patients, to fatal side effect. To date, there is no prediction model incorporating frailty in clincal practice. This study aims to develop prediction model which includes frailty state evaluation in predicting severe chemotoxicity in elderly. Methods. A retrospective cohort study using secondary data of elderly underwent chemotherapy during 2019-2021 was conducted in Cipto Mangunkusumo Hospital. Data of determinants ( sex, age, polypharmacy, frailty status, nutritional status, depression, cognitive status, cancer type, polychemotherapy, and functional status) and the incidence severe chemotherapy side effect according to grade 3-5 CTCAE were collected. Data was analyzed to develop prediction model with Cox regression using SPSS Results. Of 193 subjects, most of them are male, with median age of 65.6 (IQR 60-82) years old. Severe chemotoxicity was found in 36% of the subjects. Prediction model consists of polypharmacy, number of chemotherapy drugs, cancer type and frailty status was developed. The model has AUC of 0.79 (95% CI 0.70-0.88), p value 0,01 Conclusion. A prognostic Model consists of polypharmacy, number of chemotherapy drugs, cancer type and frailty status can predict incidence of severe chemotoxicity in elderly with AUC 0.79 (95%CI 0.70-0.88)
T-6596
Depok : FKM-UI, 2023
S2 - Tesis Pusat Informasi Kesehatan Masyarakat
☉
Andree Kurniawan; Promotor: Ratna Djuwita; Ko Promotor: Asri C. Adisasmita, Sonar Soni Panigoro; Penguji: Noorwati Sutandyo, Fiastuti Witjaksono, Tirza Z. Tamin, Rachmat Sumantri, Dwi Savitri Rivami
Abstrak:
Latar Belakang: Masih terbatas data hubungan sarkopenia dengan toksisitas kemoterapi dan kualitas hidup. Tujuan studi adalah untuk mengetahui peran sarkopenia terhadap toksisitas kemoterapi dan perubahan skor kualitas hidup setelah pasien kanker payudara Metode: Studi kohort prospektif pada pasien kanker payudara perempuan berusia 18-59 tahun yang menjalani kemoterapi pertama dilakukan evaluasi sarkopenia dengan analisa Bio-impedans dan dinamometer JAMAR. Evaluasi toksisitas kemoterapi dan kualitas hidup dengan kuesioner National cancer Institute common toxicity criteria dan kuesioner European Organization for Research and Treatment of Cancer Core Quality of life 30 dan BRE-23. Hasil: Sebanyak 128 subyek kanker payudara dengan median usia 47(25-59) tahun, 39,1% dengan status gizi gemuk, 56,3% dengan stadium 2, 51,6% belum menopause, dan 51,6% mendapat kemoterapi berbasis Taxan. Sarkopenia sebelum kemoterapi berisiko dengan toksisistas pasca kemoterapi pertama dengan adjusted rasio odds (OR) 1,74(0,62-4,86), pasca kemoterapi kedua adjusted OR 40,34 (2,54-641,19), dan pasca kemoterapi ketiga adjusted OR 3,98 (0,14-114,01). Sarkopenia berisiko terhadap perubahan skor kualitas hidup pasca tiga siklus kemoterapi untuk domain kehilangan nafsu makan dengan adjusted OR 2,23(0,27-18,63), domain konstipasi dengan adjusted OR 3,42(0,75-15,50), dan domain kesulitan finansial dengan adjusted OR 5,50(1,41-121,42). Simpulan: Sarkopenia sebelum kemoterapi berhubungan dengan toksisitas kemoterapi dan penurunan skor kualitas hidup untuk beberapa domain skala gejala
Background: There was still limited data whether sarcopenia related to chemotherapy toxicity and impacted to quality of life. The aim is to know the role of sarcopenia on chemotherapy toxicity and changed of quality of life after breast cancer patients. Methods: This prospective cohort study was conducted in breast cancer women patients with age 18 to 59-year old who underwent chemotherapy, will be evaluated sarcopenia with Bio-Impedans analysis and JAMAR dynamometer. Evaluation of chemotherapy toxicity and quality of life with National cancer institute common toxicity criteria and European Organization for research and treatment of cancer care quality of life 30 and BRE-23. Results: A total of 128 breast cancer subjects with median age 47(25-59) year old, 39.1% with obese, 56.3% with stage 2 disease. Sarcopenia before chemotherapy associated with toxicities after first, second, and third cycles of chemotherapy with adjusted OR 1.73(0.62-4.86); 40.34(2.54-641.19); and 3.98(0.14-114.01), respectively. Sarcopenia associated with changed of quality of life scores of loss of appetite, constipation, and financial loss domains with adjusted OR 2.23(0.27-18.63), 3.42(0.75-15.50), and 5.50(1.41-21.42) respectively after underwent three cycles of chemotherapy. Conclusion: Sarcopenia before chemotherapy associated with chemotherapy toxicity and decreased quality of life score for several domain of symptom scales
Read More
Background: There was still limited data whether sarcopenia related to chemotherapy toxicity and impacted to quality of life. The aim is to know the role of sarcopenia on chemotherapy toxicity and changed of quality of life after breast cancer patients. Methods: This prospective cohort study was conducted in breast cancer women patients with age 18 to 59-year old who underwent chemotherapy, will be evaluated sarcopenia with Bio-Impedans analysis and JAMAR dynamometer. Evaluation of chemotherapy toxicity and quality of life with National cancer institute common toxicity criteria and European Organization for research and treatment of cancer care quality of life 30 and BRE-23. Results: A total of 128 breast cancer subjects with median age 47(25-59) year old, 39.1% with obese, 56.3% with stage 2 disease. Sarcopenia before chemotherapy associated with toxicities after first, second, and third cycles of chemotherapy with adjusted OR 1.73(0.62-4.86); 40.34(2.54-641.19); and 3.98(0.14-114.01), respectively. Sarcopenia associated with changed of quality of life scores of loss of appetite, constipation, and financial loss domains with adjusted OR 2.23(0.27-18.63), 3.42(0.75-15.50), and 5.50(1.41-21.42) respectively after underwent three cycles of chemotherapy. Conclusion: Sarcopenia before chemotherapy associated with chemotherapy toxicity and decreased quality of life score for several domain of symptom scales
D-445
Depok : FKM-UI, 2021
S3 - Disertasi Pusat Informasi Kesehatan Masyarakat
☉